T-Knife is a spin-off of the Max-Delbrück-Center (MDC) Berlin founded in 2017 by Prof. Thomas Blankenstein, Dr. Elisa Kieback and Holger Specht. The Berlin-based Biotech company develops T cell receptors (TCRs) for T cell therapy of cancer which are derived from T-Knife’s proprietary Humanized TCR Mice. Humanized TCR mice carry the entire human TCRαβ gene loci and recombine a broad repertoire of fully human TCRs. This technology allows highly efficient generation and selection of TCRs for virtually any human tumor antigen. Since the mouse immune system is not tolerant to most human cancer antigens the obtained TCRs are of optimal affinity for cancer therapy.
The company has a broad expertise in tumor target selection, TCR sequence isolation and optimization, transgenic TCR expression and characterization. A clinical phase I trial with T-knife´s TCR lead candidate targeting MAGE-A1 for patients with multiple myeloma will start recruiting by the end of 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Headquarters

Berlin, Berlin
Specialties

immunoncology, tumor immunology, T cell receptor, adoptive T cell therapy, cell therapy, gene therapy, TCR gene transfer, TCR generation, TCR characterization, cancer testis antigens, tumor antigens, target selection, retroviral vectors, neoepitopes, Multiple myeloma, neoantigens, and gene therapy